Components of Varicella and Zoster Vaccines	Excipients Table Allergens Table Components Table
Indication Active immunity against varicella-zoster virus Prevention of shingles in individuals 60 years and older Proprietary Name Varivax Zostavax Manufacturer Merck Merck Viability Live, attenuated Live, attenuated Microorganism Double-stranded DNA varicella zoster virus, human herpes virus 3, genus Varicella virus Oka/Merck strain Dosage, Route 0.5 mL 0.65 mL Route Subcutaneous Subcutaneous Dose form Lyophilized powder for suspension Lyophilized preparation Appearance White powder yielding a clear, colorless to pale yellow liquid Semi-hazy to translucent, off-white to pale yellow liquid Concentration (per 0.5 mL) Oka/Merck varicella virus 1350 PFU Oka/Merck varicella virus 19,400 PFU Preservatives None None Adjuvant None None Excipients Sucrose, 25 mg Hydrolyzed gelatin, 12. 5 mg Sodium chloride, 3.2 mg Monosodium L-glutamate, 0.5 mg Sodium phosphate dibasic, 0.45 mg Potassium phosphate monobasic, 0.08 mg Potassium chloride, 0.08 mg   Residual components of: MRC-5 cells including DNA and proteins   Trace quantities of: Sodium phosphate monobasic Ethylenediaminetetraacetic acid (EDTA) Neomycin Fetal bovine serum Sucrose, 31.16 mg Hydrolyzed gelatin (porcine), 15.58 mg Sodium chloride, 3.99 mg Monosodium L-glutamate, 0.62 mg Sodium phosphate dibasic, 0.57 mg Potassium phosphate monobasic, 0.10 mg Potassium chloride, 0.10 mg   Residual components of: MRC-5 cells including DNA and proteins   Trace quantities of: Neomycin Fetal bovine serum Allergens Hydrolyzed gelatin, 12.5 mg Neomycin, trace amounts Hydrolyzed gelatin, 15.58 mg Neomycin, trace amounts Media MRC-5 human diploid-cell culture MRC-5 human diploid-cell culture Packaging Vial, Single-dose +10 vials of diluent; 10 single-dose vials + 10 vials diluent Vial, Single-dose +10 vials of diluent; 10 single-dose vials + 10 vials diluent Routine Storage -15° C or colder until up to 72 hours before reconstitution, then stored at 2 to 8° C (35-46° F) for up to 72 hours -15° C or colder until reconstituted for injection updated September 2006
This page was last updated on August 21, 2012 © 2006 Institute for Vaccine Safety